Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Celator Pharmaceuticals Inc (CPXX)
|
Add to portfolio |
|
|
|
| Price: |
$13.76
| | Metrics |
| OS: |
42.5
|
M
| |
-67
|
% ROE
|
| Market cap: |
$584
|
M
| |
-677
|
% ROIC
|
|
Net cash:
|
$41
|
M
| |
$0.97
|
per share
|
|
EV:
|
$543
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($18.7)
|
M
| |
|
|
|
EBIT
|
($18.9)
|
M
| |
|
|
| EPS |
($1.03)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-05 | Dec-31-03 |
| Revenues | 1.4 | 1.5 | 0.6 | 1.5 | 10.6 | 0.0 | 0.0 |
| Revenue growth | -6.5% | 175.0% | -61.6% | -86.2% | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 20.8 | 0.0 | 0.0 |
| Gross profit | 1.4 | 1.5 | 0.6 | 1.5 | -10.2 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | -96.1% | | |
| Selling, general and administrative | | | | | | 0.0 | 0.0 |
| Research and development | 11.8 | 11.9 | 9.4 | 4.9 | | | |
| General and administrative | 7.7 | 7.3 | 5.4 | 4.1 | 3.9 | 0.0 | 0.0 |
| EBIT | -18.2 | -17.8 | -14.5 | -7.9 | -14.6 | 0.0 | 0.0 |
| EBIT margin | -1261.0% | -1156.0% | -2582.0% | -541.4% | -137.4% | | |
| Pre-tax income | -20.0 | -18.8 | -22.3 | -12.3 | -15.1 | -8.9 | -3.5 |
| Income taxes | -0.7 | -1.9 | -1.4 | -1.4 | -1.0 | 0.0 | 0.0 |
| Tax rate | 3.4% | 10.3% | 6.3% | 11.1% | 6.4% | 0.0% | 0.0% |
| Net income | -19.3 | -16.9 | -20.8 | -10.9 | -14.2 | -8.9 | -3.5 |
| Net margin | -1338.6% | -1095.5% | -3715.0% | -746.1% | -133.5% | | |
| |
| Diluted EPS | ($0.57) | ($0.62) | ($0.95) | ($0.88) | ($1.81) | | |
| Shares outstanding (diluted) | 33.9 | 27.4 | 22.0 | 12.4 | 7.8 | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|